Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the supplementary application concerning the transfer of marketing authorization holder of Clopidogrel Hydrogen Sulfate Tablets. This approval follows a technology transfer agreement with Beijing Sihuan Pharmaceutical Company Limited, allowing Xinhua Pharmaceutical to acquire the marketing and sales license, along with related rights and interests, for the product. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and expand its product offerings in the pharmaceutical sector.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, primarily engaged in the production and marketing of prescription drugs. The company focuses on the pharmaceutical industry, with a particular emphasis on the development and commercialization of various drug products.
YTD Price Performance: -3.27%
Average Trading Volume: 3,324,144
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$8.91B
For an in-depth examination of 0719 stock, go to TipRanks’ Stock Analysis page.